These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9724573)

  • 21. Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs.
    Kim SH; Kwon JW; Kim WB; Lee MG
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2524-7. PubMed ID: 10508037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian estimation of pharmacokinetic parameters of vancomycin in patients with decreasing renal function.
    Yamamoto T; Terakawa H; Hisaka A; Suzuki H
    J Pharm Sci; 2012 Aug; 101(8):2968-75. PubMed ID: 22570265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment.
    Hirai T; Hanada K; Kanno A; Akashi M; Itoh T
    Eur J Clin Pharmacol; 2019 Jun; 75(6):859-866. PubMed ID: 30770940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time-Dependent Alterations of Vancomycin-Induced Nephrotoxicity in Mice.
    Takigawa M; Masutomi H; Kishimoto Y; Shimazaki Y; Hamano Y; Kondo Y; Arai T; Lee J; Ishii T; Mori Y; Ishigami A
    Biol Pharm Bull; 2017; 40(7):975-983. PubMed ID: 28674262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dependent kinetics of cilastatin in laboratory animals.
    Lin JH; Chen IW; Ulm EH
    Drug Metab Dispos; 1989; 17(4):426-32. PubMed ID: 2571484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephroprotective effect of cilastatin in allogeneic bone marrow transplantation. Results from a retrospective analysis.
    Gruss E; Tomás JF; Bernis C; Rodriguez F; Traver JA; Fernández-Rañada JM
    Bone Marrow Transplant; 1996 Oct; 18(4):761-5. PubMed ID: 8899192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Modification of vancomycin nephrotoxicity by other antibiotics in rats].
    Itoh F; Sato K; Harauchi T; Hirata M; Mizushima Y
    Jpn J Antibiot; 1995 Mar; 48(3):380-8. PubMed ID: 7752451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced renal clearance of vancomycin in rats with carcinogen-induced osteosarcoma.
    Shimada I; Iwata C; Taga S; Teramachi H; Nomura M; Miyamoto K; Tsuciya H; Wada T; Kimura K; Matsushita R
    Anticancer Res; 2012 Mar; 32(3):823-9. PubMed ID: 22399600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin.
    Hirai K; Ishii H; Shimoshikiryo T; Shimomura T; Tsuji D; Inoue K; Kadoiri T; Itoh K
    Ther Drug Monit; 2016 Dec; 38(6):706-710. PubMed ID: 27681114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency.
    Yamazaki S; Nakamura H; Yamagata S; Miura G; Hattori N; Shinozaki K; Sadahiro T; Toyoda A; Nakasa H; Ariyoshi N; Oda S; Harigaya K; Kitada M
    Int J Clin Pharmacol Ther; 2009 Nov; 47(11):701-6. PubMed ID: 19840535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelial, renal and hepatic variables in Wistar rats treated with Vancomycin.
    Bruniera FR; Ferreira FM; Savioli LR; Bacci MR; Feder D; Pereira EC; Pedreira ML; Peterlini MA; Perazzo FF; Azzalis LA; Rosa PC; Junqueira VB; Sato MA; Fonseca FL
    An Acad Bras Cienc; 2014 Dec; 86(4):1963-72. PubMed ID: 25590732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity.
    Hori Y; Aoki N; Kuwahara S; Hosojima M; Kaseda R; Goto S; Iida T; De S; Kabasawa H; Kaneko R; Aoki H; Tanabe Y; Kagamu H; Narita I; Kikuchi T; Saito A
    J Am Soc Nephrol; 2017 Jun; 28(6):1783-1791. PubMed ID: 28052987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of cerebral fluid drainage on the pharmacokinetics of vancomycin in neurosurgical patients.
    Ichie T; Urano K; Suzuki D; Okada T; Kobayashi N; Hayashi H; Sugiura Y; Yamamura K; Sugiyama T
    Pharmazie; 2015 Jun; 70(6):404-9. PubMed ID: 26189303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An extremely high bioavailability of orally administered vancomycin in a patient with severe colitis and renal insufficiency.
    Yamazaki S; Suzuki T; Suzuki T; Takatsuka H; Ishikawa M; Hattori N; Fujishiro T; Miyauchi H; Oami T; Ariyoshi N; Oda S; Matsubara H; Ishii I
    J Infect Chemother; 2017 Dec; 23(12):848-851. PubMed ID: 28923303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
    Yousif T; Pooyeh S; Hannemann J; Baumann J; Tauber R; Baumann K
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmented Renal Clearance in Pediatric Patients With Febrile Neutropenia Associated With Vancomycin Clearance.
    Hirai K; Ihara S; Kinae A; Ikegaya K; Suzuki M; Hirano K; Itoh K
    Ther Drug Monit; 2016 Jun; 38(3):393-7. PubMed ID: 27172381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
    Dailly E; Le Floch R; Deslandes G; Pannier M; Jolliet P
    Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin pharmacokinetics in critically ill patients receiving continuous haemodiafiltration with a polyethyleneimine-coated polyacrylonitrile membrane.
    Tsuruyama M; Yamashina T; Tsuruta M; Tsukada H; Fujimoto A; Nagano M; Kawamata Y; Takashima S; Hiraki Y
    J Clin Pharm Ther; 2020 Oct; 45(5):1143-1148. PubMed ID: 32497268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.
    Yu YX; Lu J; Lu HD; Li L; Li JJ; Shi L; Duan LF; Zhuang ZW; Xue SD; Shen Y; Tang L
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e6-e14. PubMed ID: 33414258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cilastatin attenuates cisplatin-induced proximal tubular cell damage.
    Camano S; Lazaro A; Moreno-Gordaliza E; Torres AM; de Lucas C; Humanes B; Lazaro JA; Milagros Gomez-Gomez M; Bosca L; Tejedor A
    J Pharmacol Exp Ther; 2010 Aug; 334(2):419-29. PubMed ID: 20435919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.